Key result
Reduced-dose DOACs match standard doses for recurrent VTE while cutting clinically relevant nonmajor bleeding.
Why the study?
Extended anticoagulation reduces recurrent VTE in cancer-associated thrombosis, but full-dose therapy increases bleeding complications, leading to reduced-dose DOACs being proposed as a safer long-term option.
Does reduced-dose DOAC therapy reduce bleeding without compromising efficacy in preventing recurrent VTE in patients with cancer-associated thrombosis?
Meta-Analysis (n=2,709)
Does reduced-dose DOAC therapy reduce bleeding without compromising efficacy in preventing recurrent VTE in patients with cancer-associated thrombosis?
Reduced-dose DOACs offer a safer bleeding profile with comparable efficacy to standard-dose DOACs for the extended treatment of cancer-associated thrombosis.
No takes yet. Share an insight, caveat, or question.
Supports reduced-dose DOACs for extended cancer-associated thrombosis to lower bleeding; extends RCT meta-analysis evidence for de-escalation.
Matos et al. (2026) conducted a meta-analysis in Cancer-associated thrombosis (n=2,709). Direct oral anticoagulants (DOACs) vs. Standard-dose DOACs was evaluated on Recurrent VTE, major bleeding, clinically relevant nonmajor bleeding, all-cause mortality, and composite bleeding. In a meta-analysis of 2,709 patients, reduced-dose DOACs showed similar efficacy to standard-dose DOACs for recurrent VTE while significantly reducing clinically relevant nonmajor bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: